Breaking Down Aclaris Therapeutics: 6 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Aclaris Therapeutics (NASDAQ:ACRS) received 6 analyst ratings in the last quarter, with an average 12-month price target of $19.17, a decline of 11.54% from the prior average. Ratings include 2 bullish, 2 somewhat bullish, and 2 indifferent. Notable actions include Stifel's Alex Thompson lowering the price target from $2.00 to $1.00 and HC Wainwright & Co.'s Raghuram Selvaraju lowering from $43.00 to $9.00. Aclaris focuses on immuno-inflammatory diseases and earns most revenue from its contract research segment. It has a low market cap, a significant revenue decline of -51.19%, a high net margin of -315.24%, an ROE of -17.41%, an ROA of -12.89%, and no debt.

December 18, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aclaris Therapeutics received mixed analyst ratings with a lowered average price target, indicating potential uncertainty in the stock's short-term performance.
The mixed analyst ratings with both bullish and indifferent views, combined with a significant reduction in the average price target, suggest that there is no clear consensus on the stock's direction. The high net margin and lack of debt are positive, but the substantial revenue decline and negative ROE and ROA may concern investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100